Table 1 Patient’s characteristics
No. patients | 102 (100) |
|---|---|
Age (years): median value (range) | 60 (33-85) |
Previous adjuvant chemotherapy | |
No | 37 (36.3) |
Yes | 39 (38.2) |
Unknown/Not available | 26 (25.5) |
Previous adjuvant endocrine therapy | |
No | 22 (21.6) |
Yes | 54 (52.9) |
Unknown/Not available | 26 (25.5) |
Histotype | |
Ductal | 76 (74.5) |
Lobular | 14 (13.7) |
Other | 7 (6.9) |
Unknown | 5 (4.9) |
Tumor stage | |
1 | 30 (29.4) |
2 | 42 (41.1) |
3 | 2 (2) |
4 | 12 (11.8) |
Unknown | 16 (15.7) |
Grade of primary tumor | |
1 | 2 (2) |
2 | 34 (33.3) |
3 | 32 (31.4) |
Unknown | 34 (33.3) |
Nodal involvement | |
0 | 24 (23.5) |
1 | 36 (35.3) |
2 | 11 (10.8) |
3 | 11 (10.8) |
Unknown | 20 (19.6) |
Metastases (at diagnosis) | |
0 | 76 (74.5) |
1 | 26 (25.5) |
Type of first-line endocrine therapy | |
Letrozole | 46 (45.1) |
Anastrozole | 22 (21.6) |
Exemestane | 26 (25.5) |
Tamoxifen | 5 (4.9) |
Fulvestrant | 3 (2.9) |